OKUR stock forecast, quote, news & analysis
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies... Show more
Why OnKure Therapeutics (OKUR) Is Up +24% in the Last 30 Days
Key Takeaways
- OKUR stock rose +24% over the past 30 days, driven by a $150 million oversubscribed private placement and positive clinical progress on lead candidate OKI-219.
- Over the past quarter, shares gained +54%, reflecting analyst buy ratings, better-than-expected Q4 earnings, and advancing Phase 1 trial data.
- Key factors include financing to support next-generation PI3Kα inhibitors, upbeat analyst targets averaging $20+, and biotech sector momentum.
- Stock exhibited volatile but upward-trending price movement amid clinical milestones and capital raise.
- Market sentiment boosted by lack of typical PI3K inhibitor side effects in early trial data.
OnKure Therapeutics (OKUR) Company Overview and Market Position
OnKure Therapeutics, Inc. (OKUR) is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines targeting biologically validated cancer drivers underserved by current therapies. Headquartered in Boulder, Colorado, and founded in 2011, the company employs a structure-based drug design platform to create tumor-agnostic small-molecule inhibitors.
Its lead asset, OKI-219, is a selective oral inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) with the H1047R mutation, advancing in the Phase 1 PIKture-01 trial for solid tumors like breast cancer. OnKure competes in the precision oncology space against larger players but differentiates via mutation-specific selectivity, potentially improving efficacy and reducing side effects like hyperglycemia or rash. These fundamentals, including a $59 million market cap and $150 million recent funding, underpin recent stock resilience amid clinical volatility typical in biotech stock analysis.
OnKure Therapeutics (OKUR) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, OKUR stock climbed from approximately $3.54 to $4.28, marking a +24% gain. The price movement was volatile yet trend-driven, with a peak near $4.59 in late March followed by consolidation around $4.20-$4.40 amid high trading volume exceeding 7 million shares on key news days.
For the past quarter, shares surged +54% from around $2.86, reflecting a steady uptrend punctuated by dips in February and sharp rallies post-earnings and financing announcements. This range-bound to breakout pattern aligns with clinical-stage biotech market trends, where stock price reacts to pipeline catalysts over macroeconomic factors.
What Drove OKUR Stock Price in the Last 30 Days
The primary catalyst was OnKure's March 27 announcement of an oversubscribed $150 million private placement at $4.15 per share, led by Access Biotechnology, to fund next-generation PI3Kα pan-mutant inhibitors OKI-345 for breast cancer and OKI-355 for vascular anomalies. This boosted cash to support operations, triggering a volume spike and initial rally, though shares dipped post-dilution before stabilizing.
Analyst actions amplified sentiment: JonesTrading issued a Buy on April 6; H.C. Wainwright lowered its target to $27 from $34 but maintained Buy on March 16, citing OKI-219's PIKture-01 data potential. Positive notes on breast cancer expansion arms and no hyperglycemia in 71-patient dosing further fueled gains. Sector tailwinds in precision oncology supported the upward price movement.
What Drove OKUR Stock Performance Over the Last Quarter
The quarter's +54% rise stemmed from sustained clinical momentum and financial updates. March 12 Q4/full-year 2025 earnings showed EPS of -$0.99 vs. consensus -$1.15 (beat), with $59.1 million cash (pre-placement) funding into 2026. PIKture-01 progress—71 patients in monotherapy/fulvestrant arms, triplet expansions with ribociclib or tucatinib—highlighted tolerability, driving mid-March surges to $4.38.
Earlier, January analyst buys from Evercore ISI and others built momentum from February lows near $2.32. Institutional interest via 13G filings and biotech demand for PI3Kα mutation-targeted therapies (PI3Kα: an enzyme often mutated in cancers) outweighed dilution fears. Cumulative impact: financing security and trial data de-risking in a high-interest-rate environment favoring cash-rich biotechs.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, scanning thousands of tickers across strategies like trend-following, mean reversion, and momentum plays on various timeframes. These curated bots display key metrics including win rate, average return, Sharpe ratio (a measure of risk-adjusted performance), and recent trades, helping investors identify relevant tools for stock analysis or automated trading. Filtered for relevance and performance, the section highlights bots succeeding in current market trends, such as biotech volatility. Explore Trending AI Robots to integrate data-driven signals into your OKUR monitoring.
OKUR Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor PIKture-01 updates, including expanded data from Parts A/B/E and triplet arms expected soon, alongside next-generation inhibitor announcements. Upcoming Q1 earnings will detail cash burn post-placement and trial enrollment. Industry trends in PI3K-targeted therapies, potential partnerships, and FDA feedback on OKI-219 could sway sentiment. Macro factors like interest rates impacting biotech funding and competitive PI3Kα developments (M&A: mergers and acquisitions) pose risks, while positive tolerability data remains a catalyst.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
OKUR's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for OKUR turned positive on May 22, 2026. Looking at past instances where OKUR's MACD turned positive, the stock continued to rise in of 12 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OKUR's RSI Oscillator exited the oversold zone, of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 21, 2026. You may want to consider a long position or call options on OKUR as a result. In of 24 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
OKUR moved above its 50-day moving average on June 17, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OKUR advanced for three days, in of 63 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 50 cases where OKUR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 14 cases where OKUR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The 10-day moving average for OKUR crossed bearishly below the 50-day moving average on May 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OKUR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
OKUR broke above its upper Bollinger Band on June 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OKUR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.982) is normal, around the industry mean (20.056). P/E Ratio (62.481) is within average values for comparable stocks, (35.868). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). OKUR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (361.304).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OKUR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement